Risolve Crowned NextRise 2025 Innovation Award Winner!

Healthcare innovation company Resol recently garnered significant spotlight by winning an Innovation Award at 'NextRise 2025'. Resol, which is opening new horizons in the mental healthcare market for sleep disorders, depression, and other conditions with its wearable device 'Sleepisol' – a device combining brainwave synchronization technology and AI biosignal analysis – successfully navigated intense competition (23:1) and was recognized for its technological prowess and commercialization capabilities. This award is another milestone proving Resol's continuous innovation. It has already clinched the 'CES 2025 Innovation Award' and the 'U.S. IDEA Design Award', and proven its potential by being selected as a 'Baby Unicorn' by the Ministry of SMEs and Startups. It is also making a prominent mark in the global market. Sleepisol has not only been sold in Korea, Japan, and the U.S., but has also built trust by passing clinical trials at Seoul National University Bundang Hospital and meeting U.S. Food and Drug Administration (FDA) safety standards. The Samsung Health-based sleep management app, 'Sleepisol Bio,' has surpassed 600,000 downloads, receiving enthusiastic responses from users. Recently, Resol was selected for Daewoong Group's 'InnoBear 4th cohort' and plans to strengthen collaboration based on digital therapeutics with key affiliates, including Daewoong Pharmaceutical. Co-CEO Kwon Goo-sung stated, "This award is a result of Resol's unique technological prowess and commercialization capabilities being officially recognized," adding, "Through cooperation with Daewoong Group, we will lead the global digital therapeutics market." Anticipation is high for how Resol's innovative journey will transform the future of the global mental healthcare market.